AgomAb Therapeutics is a Company is developing growth factor-mimetic agonistic monoclonal antibodies to regenerate damaged tissues.
Agomab Therapeutics has raised €240M across 4 funding rounds from 10 investors, most recently a Series D+ round in Oct 2024. Based in Ghent, Belgium; founded 2017; active in Healthtech. Data as of 7 Aug 2026.
Timing: in window vs cohort gap · momentum flat. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors |
|---|
| 2024-10-25 | Series D+ | €83M | Asabys Partners,Existing investors,Invus,Sanofi | View deal → |
| 2023-10-13 | Series C | €95M | Fidelity Management & Research Company LLC | View deal → |
| 2022-07-13 | Series B | €41M | Pfizer,Sabadell Asabys,Walleye Capital | View deal → |
| 2019-04-01 | Series A | €21M | Advent France Biotechnology,V-Bio Ventures | View deal → |
